Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole

Digestive and Liver Disease

Volumn 38, Issue 2, 2006, Pages 85-90

  Frazzoni, M ^a   Manno, M ^a   De Micheli, E ^a   Savarino, V ^b  

^a Nuovo Ospedale S Agostino   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Esomeprazole; Gastro oesophageal reflux disease; Lansoprazole; Oesophageal pH monitoring

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; DRUG DERIVATIVE; OMEPRAZOLE; PROTON PUMP;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ESOPHAGUS MANOMETRY; ESOPHAGUS ULCER; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; STANDING; STOMACH ACID; SUPINE POSITION; COMPARATIVE STUDY; DRUG ANTAGONISM; ESOPHAGUS; MANOMETRY; MIDDLE AGED; PH; PROSPECTIVE STUDY; SECRETION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; ESOPHAGITIS, PEPTIC; ESOPHAGUS; FEMALE; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MANOMETRY; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMPS;

EID: 33745401257     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2005.10.001     Document Type: Article

References (42)

1. DeVault K.R., and Castell D.O. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100 (2005) 190-200
2. Pisegna J., Holtmann G., Howden C.W., Katelaris P.H., Sharma P., Spechler S., et al. Review article: oesophageal complications and consequences of persistent gastro-oesophageal reflux disease. Aliment Pharmacol Ther 20 Suppl. 9 (2004) 47-56
3. Sampliner R.E., and The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 97 (2002) 1888-1895
4. Lundell L.R., Dent J., Bennett J.R., Blum A.L., Armstrong D., Galmiche J.P., et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 45 (1999) 172-180
5. Frazzoni M., De Micheli E., and Savarino V. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. Aliment Pharmacol Ther 18 (2003) 1091-1098
6. Tonini M., Vigneri S., Savarino V., and Scarpignato C. Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor. Dig Liver Dis 33 (2001) 600-606
7. Lindberg P., Keeling D., Fryklund J., Andersson T., Lundborg P., and Carlsson E. Review article: esomeprazole-enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion. Aliment Pharmacol Ther 17 (2003) 481-488
8. Castell D.O., Kahrilas P.J., Richter J.E., Vakil N.B., Johnson D.A., Zuckerman S., et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 97 (2002) 575-583
9. Fennerty M.B., Johanson J.F., Hwang C., and Sostek M. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 21 (2005) 455-463
10. Miner P., Katz P.O., Chen Y., and Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 98 (2003) 2616-2620
11. Holloway R.H., Dent J., Narielvala F., and Mackinnon A.M. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 38 (1996) 649-654
12. Barbezat G.O., Schlup M., and Lubcke R. Omeprazole therapy decreases the need for dilatation of peptic oesophageal strictures. Aliment Pharmacol Ther 13 (1999) 1041-1045
13. Avidan B., Sonnenberg A., Schnell T.G., Chejfec G., Metz A., and Sontag S.J. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 97 (2002) 1930-1936
14. Jankowski J., and Sharma P. Review article: approaches to Barrett's oesophagus treatment-the role of proton pump inhibitors and other interventions. Aliment Pharmacol Ther 19 Suppl. 1 (2004) 54-59
15. Fitzgerald R.C. Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?. Gut 54 Suppl. 1 (2005) 21-26
16. Shaheen N.J. Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 128 (2005) 1554-1566
17. Ouatu-Lascar R., Fitzgerald R.C., and Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 117 (1999) 327-335
18. El-Serag H.B., Aguirre T.V., Davis S., Kuebeler M., Bhattacharyya A., and Sampliner R.E. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 99 (2004) 1877-1883
19. Armstrong D., Bennett J.R., Blum A.L., Dent J., De Dombal F.T., Galmiche J.P., et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 111 (1996) 85-92
20. Frazzoni M., Grisendi A., Lanzani A., Melotti G., and De Micheli E. Laparoscopic fundoplication versus lansoprazole for gastrooesophageal reflux disease. A pH-metric comparison. Dig Liver Dis 34 (2002) 99-104
21. Passaretti S., Zaninotto G., Di Martino N., Leo P., Costantini M., and Baldi F. Standards for oesophageal manometry. A position statement from the Gruppo Italiano di Studio Motilità Apparato Digerente (GISMAD). Dig Liver Dis 32 (2000) 46-55
22. Richter J.E., Bradley L.A., DeMeester T.R., and Wu W.C. Normal 24-hour ambulatory esophageal pH values. Influence of study center, pH electrode, age, and gender. Dig Dis Sci 37 (1992) 849-856
23. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 122 (2002) 625-632
24. Dent J. Definition of reflux disease and its separation from dyspepsia. Gut 50 Suppl. 4 (2002) iv17-iv20
25. Johnson D.A., Stacy T., Ryan M., Wootton T., Willis J., Hornbuckle K., et al. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 22 (2005) 129-134
26. Frazzoni M., De Micheli E., Grisendi A., and Savarino V. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison. Aliment Pharmacol Ther 16 (2002) 35-39
27. Frazzoni M., De Micheli E., Grisendi A., and Savarino V. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. Aliment Pharmacol Ther 17 (2003) 235-241
28. Frazzoni M., De Micheli E., Grisendi A., and Savarino V. Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression. Aliment Pharmacol Ther 16 (2002) 881-886
29. Mittal R.K., Lange R.C., and McCallum R.W. Identification and mechanism of delayed acid clearance in subjects with hiatus hernia. Gastroenterology 92 (1987) 130-135
30. Sloan S., and Kahrilas P.J. Impairment of esophageal emptying with hiatal hernia. Gastroenterology 100 (1991) 596-605
31. Patti M., Goldberg H.I., Arcerito M., Bortolasi L., Tong J., and Way L.W. Hiatal hernia size affects lower esophageal sphincter function, esophageal acid exposure, and the degree of mucosal injury. Am J Surg 171 (1996) 182-186
32. Pandolfino J.E., Shi G., Trueworthy B., and Kahrilas P.J. Esophagogastric junction opening during relaxation distinguishes nonhernia reflux patients, hernia patients, and normal subjects. Gastroenterology 125 (2003) 1258-1260
33. Kahrilas P.J., and Quigley E.M.M. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 110 (1996) 1982-1986
34. Hatlebakk J.G., Katz P.O., Kuo B., and Castell D.O. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 12 (1998) 1235-1240
35. Pehlivanov N.D., Olyaee M., Sarosiek I., and McCallum R.W. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. Aliment Pharmacol Ther 18 (2003) 1-8
36. Heudebert G.R., Marks R., Mel Wilcox C., and Centor R.M. Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. Gastroenterology 112 (1997) 1078-1086
37. Shepherd N.A. Barrett's oesophagus and proton pump inhibitors: a pathological perspective. Gut 46 (2000) 147-149
38. Wolfsen H.C., Hemminger L.L., Wallace M.B., and Devault K.R. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer. Aliment Pharmacol Ther 20 (2004) 1125-1131
39. Ouatu-Lascar R., and Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalisation of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 93 (1998) 711-716
40. Gerson L.B., Boparai V., Ullah N., and Triadafilopoulos G. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther 20 (2004) 637-643
41. Milkes D., Gerson L.B., and Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalisation of intraesophageal and intragastric pH in patients with Gastroesophageal Reflux Disease (GERD). Am J Gastroenterol 99 (2004) 991-996
42. Fass R., Sampliner R.E., Malagon I.B., Hayden C.W., Camargo L., Wendel C.S., et al. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 14 (2000) 597-602